Relating to exemption of prescription drug sales; prescribing an effective date.
Summary
House Bill 2199 amends Oregon’s corporate activity tax law to exempt receipts from the sale of prescription drugs by licensed retail pharmacies from the definition of “commercial activity.” Under the bill, those prescription drug sales would no longer be included in the tax base used to calculate the corporate activity tax. The measure also removes existing language that limited the exemption to “eligible pharmacies” with nine or fewer locations, expanding the exemption to all licensed retail pharmacies.
The exemption would apply to tax years beginning on or after January 1, 2026, and the act would take effect on the 91st day after the 2025 regular session adjourns sine die. In practical terms, the bill would reduce corporate activity tax liability for pharmacies by excluding prescription drug sales receipts from taxation, which could affect pharmacy finances, state tax collections, and the administration of the CAT for the Oregon Department of Revenue.
Impact
HB 2199 would amend ORS 317A.123 to broaden the prescription-drug-sales exemption from the corporate activity tax and remove the prior small-pharmacy limitation. It changes state tax law by excluding amounts received by any pharmacy for prescription drug sales from “commercial activity” under ORS 317A.100 and from the tax imposed under ORS 317A.116. The bill would apply prospectively to tax years beginning on or after January 1, 2026, affecting licensed retail pharmacies statewide and reducing the CAT base for those transactions.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the available context suggests a straightforward policy proposal with no documented public controversy in the materials provided. The measure appears aimed at tax relief for pharmacies, especially by expanding an existing exemption to all pharmacies rather than only smaller ones. Because no committee discussion or vote history is included, there is no evidence here of formal support or opposition, though the policy direction is clearly favorable to pharmacies and potentially unfavorable to state revenue.
Contention
The main policy issue embedded in the bill is whether prescription drug sales should be fully excluded from the corporate activity tax and whether that exemption should apply to all licensed retail pharmacies rather than only smaller, “eligible” pharmacies. Supporters would likely view the bill as reducing tax burden on pharmacies and preserving access to prescription services, while opponents could raise concerns about narrowing the CAT tax base and reducing state revenue. No specific legislators, stakeholders, or arguments are identified in the provided committee or vote materials.